Online First

In April 2016, venetoclax (Venclexta; Janssen) became the first BCL-2 inhibitor to be approved by the FDA for relapsed, high-risk chronic lymphocytic leukemia.
The United States is the only profit-motivated healthcare system in the world, and perhaps it is no coincidence that this country also has the most expensive healthcare of any nation.
An estimated 7.5 million people in the United States have psoriasis, a chronic, inflammatory, autoimmune disease.
On September 23, 2016, the FDA approved adalimumab-atto (Amjevita; Amgen) as a biosimilar to adalimumab (Humira; AbbVie) for the treatment of several indications and inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; moderate-to-severe Crohn’s disease; moderate-to-severe ulcerative colitis; and moderate-to-severe plaque psoriasis.
The FDA approved a first-of-its-kind device, Medtronic’s MiniMed 670G hybrid closed looped system, that will automatically monitor glucose and provide basal insulin doses in patients aged ≥14 years with type 1 diabetes. The MiniMed 670G hybrid closed looped system acts as an artificial pancreas, with little or no input needed from the user.
Urothelial carcinoma (also known as transitional-cell carcinoma) is the most common subtype of bladder cancer, accounting for more than 90% of bladder cancer diagnoses in the United States. In 2016, nearly 77,000 cases of bladder cancer are expected to be diagnosed in the United States, and more than 16,000 people will die from this disease. The incidence of bladder cancer increases with age, with a median age of 73 years at diagnosis.
On March 30, 2016, the FDA approved defibrotide sodium (Defitelio; Jazz Pharmaceuticals) for hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction after hematopoietic stem-cell transplant. This is the first drug approved for severe hepatic VOD. “The approval of Defitelio fills a significant need in the transplantation community to treat this rare but frequently fatal complication,” said Richard Pazdur, MD.
On January 21, 2015, secukinumab (Cosentyx; Novartis), a human IL-17A antagonist, was approved by the US Food and Drug Administration (FDA) for the treatment of adults with moderate-to-severe plaque psoriasis.
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non–small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.
Page 1 of 2
Results 1 - 10 of 11
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME